Abeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida

MT Newswires Live

Yesterday

Abeona Therapeutics (ABEO) said Wednesday that the University of Florida Health in Gainesville has become the eighth Qualified Treatment Center for administering ZEVASKYN, its gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.

UF Health is the sole ZEVASKYN treatment center in the Southeastern US, according to the company. The center has begun identifying and onboarding eligible patients, it said.

ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric RDEB patients and is designed to introduce a functional COL7A1 gene into patients' own skin cells, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/2667201988"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667201988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667201988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667201988","market":"nz","top_or_hot":-1,"title":"Abeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida","media":"MT Newswires Live","content":"<html><body><p> Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ABEO) said Wednesday that the University of Florida <a href=\"https://laohu8.com/S/HIT\">Health in</a> Gainesville has become the eighth Qualified Treatment Center for administering ZEVASKYN, its gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.</p><p>UF Health is the sole ZEVASKYN treatment center in the Southeastern US, according to the company. The center has begun identifying and onboarding eligible patients, it said.</p><p>ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric RDEB patients and is designed to introduce a functional COL7A1 gene into patients' own skin cells, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-16 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ABEO) said Wednesday that the University of Florida <a href=\"https://laohu8.com/S/HIT\">Health in</a> Gainesville has become the eighth Qualified Treatment Center for administering ZEVASKYN, its gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.</p><p>UF Health is the sole ZEVASKYN treatment center in the Southeastern US, according to the company. The center has begun identifying and onboarding eligible patients, it said.</p><p>ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric RDEB patients and is designed to introduce a functional COL7A1 gene into patients' own skin cells, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667201988","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667201988","pubTimestamp":1789560285,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Abeona Therapeutics  said Wednesday that the University of Florida Health in Gainesville has become the eighth Qualified Treatment Center for administering ZEVASKYN, its gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.UF Health is the sole ZEVASKYN treatment center in the Southeastern US, according to the company. The center has begun identifying and onboarding eligible patients, it said.ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric RDEB patients and is designed to introduce a functional COL7A1 gene into patients' own skin cells, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ABEO":"Abeona Therapeutics Inc"},"translate_title":"Abeona Therapeutics 在佛罗里达州启动第 8 个 ZEVASKYN 治疗中心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEO":1.5},"content_text":"Abeona Therapeutics (ABEO) said Wednesday that the University of Florida Health in Gainesville has become the eighth Qualified Treatment Center for administering ZEVASKYN, its gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.UF Health is the sole ZEVASKYN treatment center in the Southeastern US, according to the company. The center has begun identifying and onboarding eligible patients, it said.ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric RDEB patients and is designed to introduce a functional COL7A1 gene into patients' own skin cells, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}